A recently published staffing model survey has brought new insights into oncology pharmacy operations across the country.

The Hematology/Oncology Pharmacy Association Practice Outcomes and Professional Benchmarking Committee (POPBC) Oncology Pharmacy Staffing Model Task Force developed a survey-based study in order to help provide an outline of oncology pharmacy staffing and operation practices. Distributed between September 2021 and January 2022, the survey collected baseline data and staffing metrics for oncology pharmacies - including facilities, inpatient and outpatient services, informatics/technology and more. The responses not only provided further insight into the unique oncology pharmacy operations and staffing models around the country, but also highlighted a need for staffing model benchmarking and metrics.

The full results are now published in the Journal of Oncology Pharmacy Practice.


Authors: Andrew Wechter, Anne M. McDonnell, Emily Zimdars, Leanne Sakamoto and Mark Hamm

Read the full article here

An image of pancreatic cancer
HOPA News Late Breaking News

Late-Breaking HOPA News: RASolute 302 Breakthrough in Metastatic Pancreatic Adenocarcinoma

Michael Arnold, PharmD, discusses the very encouraging results from the RASolute 302 trial, a potential breakthrough in pancreatic cancer threapy.

Blood stem cells
HOPA News Late Breaking News

Late-Breaking HOPA News: Precision-T: Orca-T and the Evolution of GVHD Prophylaxis in Allogeneic Transplantation

Nathan Schieldt, PharmD, BCOP, discusses allogeneic hematopoietic stem cell transplantation's place as a potentially curative therapy for high-risk hematologic malignancies and how Orca-T provides a novel approach to allo-HSCT.

An image of multiple myeloma cells
HOPA News Late Breaking News

Late-Breaking HOPA News: Redefining Relapse: What MajesTEC-3 Means for the Treatment of Multiple Myeloma

Sanja Zepcan, PharmD, BCPS, BCOP, and Emily Rux, PharmD, BCOP, discuss the clinical questions raised by the recent MajesTEC-3 trial and the potential changes it finds in the treatment of multiple myeloma.